Impact of respiratory virus molecular testing on antibiotic utilization in community-acquired pneumonia

    loading  Checking for direct PDF access through Ovid


HighlightsViral pathogens account for approximately 30% of community-acquired pneumonia (CAP) cases.Polymerase chain reaction respiratory virus panels can identify specific viral pathogens in CAP.Study patients with viral CAP had only a minor decrease in antibiotic utilization.Additional interventions are needed to reduce antibiotic use in viral CAP.We compared the clinical characteristics and antibiotic therapy of community-acquired pneumonia patients who were positive on a respiratory virus molecular test (polymerase chain reaction) with those who were negative. We found that respiratory virus molecular polymerase chain reaction testing has a minimal impact on reducing antibiotic utilization among viral pneumonia patients.

    loading  Loading Related Articles